Skip to main content
MNKD
NASDAQ Life Sciences

MannKind 10-Q: Q3 Revenue Up 24% to $101.9M, Net Loss Widens to $23.2M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.79
Mkt Cap
$1.209B
52W Low
$2.23
52W High
$6.51
52W Position info
70% above low
Off High info
42% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

MNKD sits 70% above its 52-week low of $2.23.

Summary

MannKind's Q3 revenue rose 24% to $101.9 million on doubled product sales, but SG&A more than doubled and the net loss widened to $23.2 million, leaving $96.6 million in cash and investments against a $325 million term loan.


Key Events · Earnings and Guidance · MNKD

  • Q3 Revenue Up 24% to $101.9M

    Total revenues rose to $101.9 million from $82.1 million a year ago, with commercial product sales doubling to $45.0 million and royalties up 12% to $37.5 million.

  • Net Loss Widens to $23.2M

    The quarter swung to a $23.2 million net loss, or $0.07 per share, from $8.0 million of net income a year earlier, as SG&A jumped 111% to $61.4 million on Furoscix promotion and ReadyFlow launch costs.

  • Cash Falls to $96.6M

    Cash, cash equivalents and investments totaled $96.6 million at September 30, 2026, down from $177.4 million at December 31, 2025, after $58.3 million of operating cash use in the first nine months.

  • Debt Load Weighs on Results

    Interest expense reached $27.0 million for nine months on the $325.0 million Blackstone term loan, which carries a 9.18% effective rate and matures August 6, 2030.


Analysis · MNKD · Life Sciences

Revenue growth is real — commercial product sales doubled to $45.0 million on Furoscix and Afrezza — but the cost of building that franchise is outrunning it. SG&A jumped 111% to $61.4 million in the quarter and $173.8 million for nine months, pushing the company to a $23.2 million quarterly loss from a $8.0 million profit a year ago. The balance sheet is the pressure point: cash, equivalents and investments fell to $96.6 million from $177.4 million at year-end, and operations consumed $58.3 million of cash in nine months versus generating $26.2 million a year earlier. Against a $325.0 million Blackstone term loan at a 9.18% effective rate, the company is now dependent on continued revenue ramp and access to capital. The July private placement's $49.8 million net proceeds went straight out the door to fund the $44.8 million CVR payment triggered by the Furoscix ReadyFlow approval.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 36.3% of the 2976 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNKD was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNKD - Latest Insights

MNKD
Nov 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.85 info
Change: +$0.090 (+2%) info
Market Cap: $1.254B info
MNKD
Sep 09, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $3.85 info
Change: -$0.430 (-10%) info
Market Cap: $1.254B info
MNKD
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $3.85 info
Change: -$0.270 (-7%) info
Market Cap: $1.254B info
MNKD
Jul 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.85 info
Change: -$0.180 (-4%) info
Market Cap: $1.254B info
MNKD
Jul 24, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $3.85 info
Change: -$0.260 (-6%) info
Market Cap: $1.254B info